1098011-54-1

Basic information

• Product Name: 1-(2-((1-(ethoxycarbonyloxy)cyclohexyl methoxycarbonylmethyl)carbamoyl)-3-phenyl propyldisulfanylmethyl)-3-methylsulfanylpropyl ammonium trifluoroacetate
• CAS NO: 1098011-54-1
• Molecular Weight: 700.862
• Mol File: 1098011-54-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(2-((1-(ethoxycarbonyloxy)cyclohexyl methoxycarbonylmethyl)carbamoyl)-3-phenyl propyldisulfanylmethyl)-3-methylsulfanylpropyl ammonium trifluoroacetate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-((1-(ethoxycarbonyloxy)cyclohexyl methoxycarbonylmethyl)carbamoyl)-3-phenyl propyldisulfanylmethyl)-3-methylsulfanylpropyl ammonium trifluoroacetate(1098011-54-1)
• EPA Substance Registry System: 1-(2-((1-(ethoxycarbonyloxy)cyclohexyl methoxycarbonylmethyl)carbamoyl)-3-phenyl propyldisulfanylmethyl)-3-methylsulfanylpropyl ammonium trifluoroacetate(1098011-54-1)

Safety Data

• Hazardous Substances Data: 1098011-54-1(Hazardous Substances Data)

Upstream product

• 141437-94-7 ((S)-1-Mercaptomethyl-3-methylsulfanyl-propyl)-carbamic acid tert-butyl ester 
• 2488-15-5 N-tert-butoxycarbonyl-L-methionine 
• 51372-93-1 (S)-tert-butyl (1-hydroxy-4-(methylthio)butan-2-yl)carbamate 
• 247093-36-3 (S)-2-(tert-butoxycarbonylamino)-4-(methylthio)butyl methanesulfonate 
• 84890-95-9 C₁₅H₂₇NO₆S 
• 139429-04-2 Thioacetic acid S-((S)-2-tert-butoxycarbonylamino-4-methylsulfanyl-butyl) ester 
• 2043-61-0 cyclohexanecarbaldehyde 
• 81363-12-4 α-chloro-αcyclohexylmethyl chloroformate 
• 102246-52-6 C₁₀H₁₇ClO₃ 
• 1616274-40-8 C₁₇H₂₉NO₇ 
• 935481-12-2 (S)-2-benzyl-3-(((S)-2-(tert-butoxycarbonylamino)-4-(methylthio)butyl)disulfanyl)propanoic acid 
• 1098011-26-7 cyclohexyl(ethoxycarbonyloxy)methyl 2-aminoacetate trifluoroacetate 
• 1616274-77-1 C₃₂H₅₀N₂O₈S₃ 
• 76-05-1 trifluoroacetic acid 

Relevant articles and documents

Discovery of 4-Aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents

Adenosine diphosphate (ADP)-mediated platelet aggregation is signaled through two distinct G protein-coupled receptors (GPCR) on the platelet surface: P2Y12 and P2Y1. Blocking P2Y12 receptor is a clinically well-validated strategy for antithrombotic therapy. P2Y1 antagonists have been shown to have the potential to provide equivalent antithrombotic efficacy as P2Y12 inhibitors with reduced bleeding in preclinical animal models. We have previously reported the discovery of a potent and orally bioavailable P2Y1 antagonist, 1. This paper describes further optimization of 1 by introducing 4-aryl groups at the hydroxylindoline in two series. In the neutral series, 10q was identified with excellent potency and desirable pharmacokinetic (PK) profile. It also demonstrated similar antithrombotic efficacy with less bleeding compared with the known P2Y 12 antagonist prasugrel in rabbit efficacy/bleeding models. In the basic series, 20c (BMS-884775) was discovered with an improved PK and liability profile over 1. These results support P2Y1 antagonism as a promising new antiplatelet target.

AMINOACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF MIXED DISULFANYL AND AMINOPEPTIDASE N INHIBITORS

The invention relates to novel compounds of formula (I): H2N-CH(R1)-CH2-S-S-CH2-CH(R2)-CONH-R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R5 is a CH(R3)-COOR4 radical, wherein R3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C1-C6, phenyl or benzyl radical. The use of the inventive compounds in the form of drugs, a pharmaceutical composition comprising said compounds, a pharmaceutically acceptable excipient, the use in conjunction of at least one type of cannabinoid derivative for potentiating the analgesic and antidepressant effect of the novel compounds of formula (I) and/or morphine or the derivatives thereof are also disclosed.